3 Reasons to Hold On to Teva Pharmaceutical's Stock
Teva Pharmaceutical Industries is a selection for the real-money Inflation-Protected Income Growth portfolio. In this brief video, portfolio manager Chuck Saletta offers three reasons why he's holding on to Teva's stock despite the company's recent challenges and the fact that its shares are essentially at the level he bought them at last year.
Help your money compound faster
Teva's dividend was key to its selection for the iPIG portfolio. A well-covered and rising dividend, reinvested over time, can help your money compound faster and could ultimately make you rich. It's as simple as that.
With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list of nine in this free report. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
- Teva's market capitalization isn't much above my revised fair-value estimate.
- Teva's balance sheet remains strong:
- Teva's dividend remains covered, probably better than its 85% payout ratio suggests.
What problems has Teva faced in 2013?
As mentioned in the video, Teva has had its share of problems in 2013. Two of the biggest were the early patent loss on its blockbuster drug Copaxone and the surprise resignation of CEO Jeremy Levin. Litigation costs in the second quarter of 2013 also pushed the company's earnings negative for the quarter. If those litigation costs were truly a one-time occurrence, then the company's earnings power and dividend coverage are stronger than its historical numbers would suggest. Only time -- and the company's future operations -- will tell.
To follow the IPIG portfolio as buy and sell decisions are made, watch Chuck's article feed by clicking here. To join The Motley Fool's free discussion board dedicated to the IPIG portfolio, simply click here.
The article 3 Reasons to Hold On to Teva Pharmaceutical's Stock originally appeared on Fool.com.Chuck Saletta owns shares of Teva Pharmaceutical Industries. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.